US20060174884A1 - Ventilation method and control of a ventilator based on same - Google Patents

Ventilation method and control of a ventilator based on same Download PDF

Info

Publication number
US20060174884A1
US20060174884A1 US11/386,807 US38680706A US2006174884A1 US 20060174884 A1 US20060174884 A1 US 20060174884A1 US 38680706 A US38680706 A US 38680706A US 2006174884 A1 US2006174884 A1 US 2006174884A1
Authority
US
United States
Prior art keywords
ventilation
airway pressure
cpap
ventilator
mode
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/386,807
Inventor
Nader Habashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/386,807 priority Critical patent/US20060174884A1/en
Publication of US20060174884A1 publication Critical patent/US20060174884A1/en
Assigned to INTENSIVE CARE ON-LINE NETWORK, INC. reassignment INTENSIVE CARE ON-LINE NETWORK, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HABASHI, NADER M.
Assigned to HABASHI, NADER M. reassignment HABASHI, NADER M. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: INTENSIVE CARE ON-LINE NETWORK, INC.
Assigned to HABASHI, NADER M. reassignment HABASHI, NADER M. CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 11368807 PREVIOUSLY RECORDED AT REEL: 033722 FRAME: 0395. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: INTENSIVE CARE ON-LINE NETWORK, INC.
Priority to US14/820,308 priority patent/US20150359983A1/en
Priority to US15/648,419 priority patent/US20180154096A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0057—Pumps therefor
    • A61M16/0066—Blowers or centrifugal pumps
    • A61M16/0069—Blowers or centrifugal pumps the speed thereof being controlled by respiratory parameters, e.g. by inhalation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
    • A61M16/022—Control means therefor
    • A61M16/024—Control means therefor including calculation means, e.g. using a processor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
    • A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
    • A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
    • A61M2016/0042—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the expiratory circuit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/33—Controlling, regulating or measuring
    • A61M2205/3331—Pressure; Flow
    • A61M2205/3334—Measuring or controlling the flow rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/50—General characteristics of the apparatus with microprocessors or computers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/202—Blood composition characteristics partial carbon oxide pressure, e.g. partial dioxide pressure (P-CO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2230/00—Measuring parameters of the user
    • A61M2230/20—Blood composition characteristics
    • A61M2230/205—Blood composition characteristics partial oxygen pressure (P-O2)

Definitions

  • the invention related to the field of ventilating human patients. More particularly, the present invention relates to an improved method of initiation, management and/or weaning of airway pressure release ventilation and for controlling a ventilator in accordance with same.
  • Airway pressure release ventilation is a mode of ventilation believed to offer advantages as a lung protective ventilator strategy.
  • APRV is a form of continuous positive airway pressure (CPAP) with an intermittent release phase from a preset CPAP level.
  • CPAP continuous positive airway pressure
  • CPAP levels can be set with the goal of optimizing recruitment without increasing the potential for over distension. Consequently, end inspiratory pressure can be limited despite more complete recruitment and ventilation can be maintained.
  • APRV is also associated with reduction or elimination of sedative, inotropic and neuromuscular blocking agents.
  • APRV is a form of positive pressure ventilation that augments alveolar ventilation and lowers peak airway pressure.
  • Published data on APRV has documented airway pressure reduction on the order of 30 to 75 percent over conventional volume and pressure cycled ventilation during experimental and clinical studies. Such reduction of airway pressure may reduce the risk of VILI.
  • APRV improves ventilation to perfusion ratio (VA/Q) matching and reduces shunt fraction compared to conventional ventilation.
  • VA/Q ventilation to perfusion ratio
  • MIGET multiple inert gas dilution and excretion technique
  • MIGET multiple inert gas dilution and excretion technique
  • APRV has been associated with improved hemodynamics.
  • Calzia reported no adverse hemodynamic effects.
  • Several studies have documented improved cardiac output, blood pressure and oxygen delivery. Consideration of APRV as an alternative to pharmacological or fluid therapy in the hemodynamically-compromised, mechanically-ventilated patient has been recommended in several case reports.
  • ALI/ARDS both FRC and expiratory flow reserve is reduced. Pulmonary edema development and superimposed pressure result in increased airway closing volume and trapped volume. In addition, the reduced number of functional lung units (de-recruited lung units and enhanced airway closure) decrease expiratory flow reserve further. Low volume ventilation promotes small airway closure and gas trapping. In addition elevated levels of PEEP increase expiratory flow resistance. In addition to downstream resistance, maximal expiratory flow depends on lung volume. The elastic recoil pressure stored in the proceeding lung inflation determines the rate of passive lung deflation.
  • APRV expiratory flow is enhanced by utilization of an open breathing system and use of low (0-5 cmH 2 O) end expiratory pressure.
  • EELV is maintained by limiting the release time and titrated to the inflection point of the flow volume curve.
  • PSV required significant increases in pressure support levels (airway pressure) to match the same minute ventilation.
  • NMBA neuromuscular blocking agents
  • NMBA In addition to drug cost reduction, elimination of NMBA is thought to reduce the likelihood of associated complications such as prolonged paralysis and may facilitate weaning from mechanical ventilation.
  • End expiratory lung volume was maintained by setting PEEP levels to 2 cmH 2 O above the lower inflection point.
  • the P-V curve represents the entire respiratory system and may not adequately reflect the individual air spaces.
  • the invention further recognizes that recruitment continues above the inflection point and may continue at airway pressures beyond 30 cmH 2 O and that the primary mechanism of lung volume change may be recruitment/de-recruitment (R/D) rather than isotropic and anisotropic alveolar volume change.
  • Lung volume change to 80% of total lung capacity (TLC) may well be a result of alveolar number increase (RID) rather than alveolar size.
  • recruitment is an end inspiratory phenomenon and may be more closely related to plateau pressure rather than PEEP. Therefore, to prevent tidal recruitment/de-recruitment (RID), cyclic shear stress and low volume lung injury, the invention contemplates that higher pressure may be required to achieve complete recruitment. It is recognized that if PEEP levels are set to end inspiratory pressure in order to completely recruit the lung, the superimposition of tidal ventilation could result in over-distension and high volume lung injury despite tidal volume reduction.
  • the invention recognizes that recruitment is an inflation phenomenon which continues beyond conventional PEEP levels. Recruitment requires enough pressure to overcome threshold-opening pressures and the superimposed pressure of the airspace. Plateau pressure or continuous positive airway pressure (CPAP) rather than PEEP level may be more appropriate determinants of full lung recruitment. PEEP conceptually prevents de-recruitment after a sustained inflation. Airway closure or de-recruitment is a deflation phenomenon. Therefore, in accordance with the invention, PEEP may be more suitable set to the inflection point of the deflation limb of the P-V curve rather than that of the inflation limb.
  • CPAP continuous positive airway pressure
  • plateau or CPAP levels should be utilized for bringing about airway opening (recruitment), allowing substantially complete recruitment.
  • complete recruitment requires constant inflation in order to sustain recruitment.
  • sustained recruitment facilitates ventilation on the deflation limb. Ventilation occurs on the deflation limb of the P-V curve only after a sustained recruitment maneuver. Sustained inflation pushes the P-V curve to the outer envelope on to the deflation limb. Stress relaxation accounts for a pressure reduction on the order of 20% within the initial 4 seconds of inflation.
  • APRV mode ventilation is established based on an initial set of ventilation parameters selected as described in further detail below.
  • the parameter, T 2 which defines the duration of the ventilator release phase, is monitored and adjusted according to at least one and preferable several alternative methods.
  • One method is to measure the expiratory gas flow rate during expiration and to adjust T 2 , if necessary, such that T 2 is terminated when the rate of expiratory gas flow is at a value of about 25% to 50% of its absolute peak value during expiration.
  • the ventilator is controlled to monitor the expiratory gas flow rate and terminate the release phase when the flow rate reaches a value within the aforementioned range.
  • Another method is to monitor expiratory flow and determine, based on the flow pattern, whether the flow is of a restrictive or obstructive nature, and adjust T 2 accordingly.
  • the expiratory flow is monitored for the presence of an inflection point and T 2 is adjusted as required to substantially eliminate or at least reduce the inflection point.
  • the highest airway pressure achieved during inspiration (P 1 ) and the duration of the positive pressure phase (T 1 ) are both incrementally increased substantially contemporaneously once or more as needed until blood carbon dioxide declines to an acceptable level.
  • weaning from ventilation is carried out by initiating a series of successive reductions in P 1 , each of which is accompanied by a substantially contemporaneous, increase in the duration of inspiration T 1 such that over time, ventilation is transitioned from APRV to a substantially CPAP mode.
  • Applicant's ventilation method and method for controlling a ventilation apparatus based on same provides significant advantages over the prior art. These advantages include an increase in vent free days, lower ventilator-related drug costs, reduced ventilator associated complications, reduced likelihood of high volume lung injury, and reduced likelihood of low volume lung injury.
  • FIG. 1 is a flowchart illustrating a preferred embodiment of a ventilation method and control of a ventilator based on same according to the invention
  • FIG. 2 is a schematic airway pressure versus time tracing for airway pressure release ventilation
  • FIG. 3 is a airway pressure versus time tracing during the inspiratory (P 1 ) phase of ventilation
  • FIG. 4 is an airway volume versus pressure curve illustrating a shift from the inspiratory limb to the expiratory limb thereof;
  • FIG. 5 is an inspiratory and expiratory gas flow versus time tracing for airway pressure release ventilation
  • FIG. 6 is an expiratory gas flow versus time tracing
  • FIG. 7 is a set of expiratory gas flow versus time tracing illustrating determination of whether flow pattern is normal, restrictive or obstructive based on the shape of the tracing, and
  • FIG. 8 is a set of airway pressure versus time tracings illustrating ventilation weaning by successive reductions in pressure PI and substantially contemporaneous increases in time T 1 .
  • An operator interface coupled to the control unit typically includes a graphical user interface as well as a keyboard and/or pointing device to enable an operator to select the operating mode of the ventilator and/or to enter or edit patient data and operating parameters such as the pressures, times, flows, and/or volumes associated with one or more ventilation cycles.
  • the invention contemplates initiating ventilation of a patient in an APRV mode based on initial oxygenation and ventilation settings.
  • the airway pressure during expiration (P 2 ) is substantially zero throughout ventilation to allow for the rapid acceleration of expiratory gas flow rates.
  • the fraction of oxygen in the inspired gas (FiO 2 ) is initially set at about 0.5 to 1.0 (i.e. about 50% to 100%).
  • the highest airway pressure achieved during inspiration (PI) must be sufficiently high to overcome airspace closing forces and initiate recruitment of lung volume.
  • PI may suitably be initialized at a default value of about 35 cmH 2 O.
  • PI may be established based either on the severity and type of lung injury or based on recruitment pressure requirements.
  • the latter method is preferred in cases where the ventilation/perfusion ratio is less than or equal to about two hundred millimeters of mercury (200 mmHg).
  • the ventilation perfusion ratio is preferably monitored continuously. It is the ratio of the partial pressure of oxygen in the blood of the patient to the fraction of oxygen present in the inspired gas (i.e. PaO 2 /FiO 2 but is commonly abbreviated as P/F).
  • P 1 is preferably initialized within the range of about 28 cmH 2 O to 35 cmH 2 O.
  • the invention contemplates establishment of P 1 at a value of between about 35 mmHg and 40 mmHg but preferably not appreciably above 40 mmHg.
  • the duration of the positive pressure phase (Ti) is established at a value within the range of about 5.0 to about 6.0 seconds unless the measured PaCO 2 is greater than about 60 mmHg.
  • a principal goal is to maintain the level of carbon dioxide in the blood of the ventilated patient (PaCo 2 ) at a level of less than or equal to about 50 mmHg.
  • PaCo 2 the level of carbon dioxide in the blood of the ventilated patient
  • arterial PaCO 2 is monitored continuously or measured as clinically indicated and the ventilator controlled to adjust ventilation as follows. Any time after ventilation has commenced, but preferably soon thereafter or promptly upon any indication of hypercarbia (PaCO 2 above about 50 mmHg), the setting of T 2 is optionally but preferably checked and re-adjusted if necessary.
  • optimal end expiratory lung volume is maintained by titration of the duration of the expiration or release phase by terminating T 2 based on expiratory gas flow.
  • the flow rate of the expiratory gas is measured by the ventilator and checked in relation to the time at which the controller of the ventilator initiates termination of the release phase.
  • the expiratory exhaust valve should be actuated to terminate the release phase T 2 , at a time when the flow rate of the expiratory gas has decreased to about 25% to 50% of its absolute peak expiratory flow rate (PEFR).
  • PEFR absolute peak expiratory flow rate
  • FIG. 5 An example is illustrated in FIG. 5 .
  • T 2 (sometimes referred to as Tlow) terminates by controlling the expiratory exhaust valve to terminate the release phase when the expiratory gas flow rate diminishes to 40% PEFR.
  • T 1 is increased by about 0.5 seconds while maintaining PI substantially unchanged. Should the patient remain hypocarbic as indicated by subsequent measure of PaCO 2 , weaning in the manner to be described may be initiated provided oxygenation is satisfactory and weaning is not otherwise contraindicated based on criteria to be described further below.
  • the hypercarbic patient though is not to be weaned.
  • the invention contemplates assessment of the expiratory flow pattern before making significant further adjustments to ventilation parameters. This assessment can readily be carried out by a software program stored within the control unit of the ventilator which carries out automated analysis of the expiration flow versus time tracing.
  • normal expiratory flow is characterized by flow which declines substantially monotonically from the onset of the release phase through its termination and does not fall off prematurely or abruptly.
  • Restrictive flow in contrast declines rapidly from the onset of the release phase to zero or a relatively small value.
  • Obstructive flow tends to be more extended in duration and is characterized by an inflection point beyond which the rate of flow falls off markedly from its initial rate.
  • FIG. 6 illustrates another example of an obstructive flow pattern.
  • the control unit of the ventilator is programmed to determine whether flow is obstructive or restrictive based on the characteristics just described. If it is determined that obstructive or restrictive flow is present, the invention contemplates adjusting T 2 before making any other significant adjustments to ventilation parameters. This can be done according to either of two alternative methods.
  • T 2 One method is to adjust T 2 to a predetermined value according to whether flow is either obstructive or restrictive but allowing T 2 to remain at its previous value if flow is normal.
  • T 2 should be adjusted to less than about 0 . 7 seconds.
  • obstructive flow calls for a T 2 of greater duration, preferably greater than about 0.7 seconds with 1.0 to 1.2 being typical.
  • PaCO 2 should then be reassessed and concomitant increases of about 0.5 seconds in T 1 and about 2 cmH 2 O in P 1 repeated as indicated in FIG. 1 until the patient is no longer hypercarbic.
  • weaning in the manner to be described may be initiated provided the ventilation goal described earlier (i.e. a PaCO 2 of less than about 50 mmHg) is met and weaning is not otherwise contraindicated.
  • P 1 is increased to a maximum of about 45 cmH 2 O and Ti is progressively further increased by about 0.5 seconds to 1.0 seconds.
  • Ventilation is controlled to maintain those goals while progressively decreasing FiO 2 and P 1 toward the levels at which initiation of weaning can be considered. More particularly, P 1 is decreased by about 1 cmH 2 O per hour while FiO 2 is decreased by about 0.05 about every thirty (30) minutes while maintaining an oxygen saturation of at least about 95%.
  • the patient's ability to maintain unassisted breathing is assessed, preferably for at least about 2 hours or more.
  • SPO 2 of at least about 0.90 and/or PaO 2 of at least about 60 mmHg;
  • CPAP at an airway pressure of about 10 cmH 2 O should be resumed and monitoring and reassessment carried out as needed.
  • criteria a) through d) above are all satisfied, the patient may be transitioned to substantially unassisted breathing such as by extubation with face mask, nasal prong oxygen or room air, T-tube breathing, tracheotomy mask breathing or use of high flow CPAP at about 5 cmH 2 O.
  • the patent should be reassessed at least about every two hours and more frequently if indicated.
  • Blood gas measurements PaO 2 and SaO 2 and PCO 2 ) on which govern control of ventilation according to the invention should be monitored not less frequently than every two hours though substantially continuous monitoring of all parameters would be considered ideal.
  • Blood gas measurements PaO 2 and SaO 2 and PaCO 2 ) that govern control of ventilation according to the invention should be monitored not less frequently than every two hours though substantially continuous monitoring of all parameters would be considered ideal.
  • At least one special assessment should be conducted daily, preferably between 0600 and 1000 hours. If not possible to do so, a delay of not more than about four hours could be tolerated. Weaning should not be initiated or continued further unless:
  • the patient is not receiving neuromuscular blocking agents and is without neuromuscular blockade
  • Systolic arterial pressure is at least about 90 mmHg without vasopressors (other than “renal” dose dopamine).
  • a trial should be conducted by ventilating the patent in CPAP mode at about 5 cmH 2 O and an FiO 2 of about 0.5 for about five (5) minutes. If the respiration rate of the patient does not exceed about 35 breaths per minute (bpm) during the five (5) minute period weaning as described above may proceed. However, if during the five (5) minute period the respiration rate exceeds about 35 bpm it should be determined whether such tachypnea is associated with anxiety. If so, administer appropriate treatment for the anxiety and repeat the trial within about four (4) hours. If tachypnea does not appear to be associated with anxiety, resume management of ventilation at the parameter settings in effect prior to the trial and resume management of ventilation as described above. Re-assess at least daily until weaning as described above can be initiated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides an improved ventilation method and method for controlling a ventilator apparatus in accordance with same. More specifically, the present invention relates to a method of controlling a ventilator apparatus comprising the steps of placing a ventilator in a mode capable of adjusting airway pressure (P) and time (T), monitoring expiratory gas flow, analyzing the expiratory gas flow over time (T) to establish an expiratory gas flow pattern, and setting and/or adjusting a low time (T2) based on the expiratory gas flow pattern. Alternatively, the present invention relates to a method of controlling a ventilator apparatus comprising the steps of placing a ventilator in a mode capable of adjusting airway pressure (P) and time (T), and setting a low airway pressure (P2) of substantially zero cmH2O.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a divisional of U.S. application Ser. No. 10/176,710 filed Jun. 20, 2002, which claims priority to U.S. Provisional Application No. 60/299,928 filed Jun. 21, 2001.
    • FIELD OF THE INVENTION
  • The invention related to the field of ventilating human patients. More particularly, the present invention relates to an improved method of initiation, management and/or weaning of airway pressure release ventilation and for controlling a ventilator in accordance with same.
    • BACKGROUND OF THE INVENTION
  • Airway pressure release ventilation (APRV) is a mode of ventilation believed to offer advantages as a lung protective ventilator strategy. APRV is a form of continuous positive airway pressure (CPAP) with an intermittent release phase from a preset CPAP level.
  • During APRV, ventilation occurs on the expiratory limb. The resultant expiratory tidal volume decreases lung volume, eliminating the need to elevate end inspiratory pressure above the upper inflection point. Therefore, tidal volume reduction is unnecessary. CPAP levels can be set with the goal of optimizing recruitment without increasing the potential for over distension. Consequently, end inspiratory pressure can be limited despite more complete recruitment and ventilation can be maintained.
  • APRV is also associated with reduction or elimination of sedative, inotropic and neuromuscular blocking agents.
  • APRV is a form of positive pressure ventilation that augments alveolar ventilation and lowers peak airway pressure. Published data on APRV has documented airway pressure reduction on the order of 30 to 75 percent over conventional volume and pressure cycled ventilation during experimental and clinical studies. Such reduction of airway pressure may reduce the risk of VILI. APRV improves ventilation to perfusion ratio (VA/Q) matching and reduces shunt fraction compared to conventional ventilation. Studies performed utilizing multiple inert gas dilution and excretion technique (MIGET) have demonstrated less shunt fraction, and dead space ventilation. Such studies suggest that APRV is associated with more uniform distribution inspired gas and less dead space ventilation than conventional positive pressure ventilation.
  • APRV has been associated with improved hemodynamics. In a 10-year review of APRV, Calzia reported no adverse hemodynamic effects. Several studies have documented improved cardiac output, blood pressure and oxygen delivery. Consideration of APRV as an alternative to pharmacological or fluid therapy in the hemodynamically-compromised, mechanically-ventilated patient has been recommended in several case reports.
  • However, most patients with ALI/ARDS exhibit expiratory flow limitations. Expiratory flow limitations results in dynamic hyperinflation and intrinsic positive end expiratory pressure (PEEP) development. In addition, ARDS patients experience increased flow resistance from external ventilator valving and gas flow path circuitry including the endotracheal tube and the external application of PEEP.
  • Several mechanisms can induce expiratory flow limitations in ALI/ARDS. In ALI/ARDS both FRC and expiratory flow reserve is reduced. Pulmonary edema development and superimposed pressure result in increased airway closing volume and trapped volume. In addition, the reduced number of functional lung units (de-recruited lung units and enhanced airway closure) decrease expiratory flow reserve further. Low volume ventilation promotes small airway closure and gas trapping. In addition elevated levels of PEEP increase expiratory flow resistance. In addition to downstream resistance, maximal expiratory flow depends on lung volume. The elastic recoil pressure stored in the proceeding lung inflation determines the rate of passive lung deflation.
  • APRV expiratory flow is enhanced by utilization of an open breathing system and use of low (0-5 cmH2O) end expiratory pressure. EELV is maintained by limiting the release time and titrated to the inflection point of the flow volume curve.
  • PSV required significant increases in pressure support levels (airway pressure) to match the same minute ventilation.
  • Conventional lung protective strategies are associated with increased use of sedative agents and neuromuscular blocking agents (NMBA).
  • In addition to drug cost reduction, elimination of NMBA is thought to reduce the likelihood of associated complications such as prolonged paralysis and may facilitate weaning from mechanical ventilation.
  • Mechanical ventilation remains the mainstay management for acute respiratory failure. In contrast, shear force stress from repetitive airway closure during the tidal cycle from mechanical ventilation results in low volume lung injury.
  • End expiratory lung volume was maintained by setting PEEP levels to 2 cmH2O above the lower inflection point.
  • Such important differences between these studies limited conclusions as to the effectiveness of low tidal ventilation limiting ventilator associated lung injury (VALI).
  • Recent completion of the large controlled randomized ARDSNet trial documented improved survival and ventilator free days utilizing low tidal volume ventilation (6 ml/kg) vs. traditional tidal volume ventilation (12 ml/kg). although the low tidal volume group (6 ml/kg) and traditional tidal volume group (12 ml/kg) groups utilized identical PEEP/FiO2 scales, PEEP levels were significantly higher in the low tidal volume group. Higher PEEP levels were required in the low tidal volume group in order to meet oxygenation goals of the study. Despite improved survival in the low tidal volume group (6 ml/kg) over traditional tidal volume group (12 ml/kg), survival was higher in the Amato study. The ARDSNet trial also failed to demonstrate any difference in the incidence of barotraumas. The higher PEEP requirements and the potential for significant intrinsic PEEP from higher respiratory frequency in the lower tidal volume group, may have obscured potential contribution of elevated end expiratory pressure on survival. Further studies are contemplated to address the issue of elevated end expiratory pressure.
  • In the prior art, utilization of the quasi-static inspiratory pressure versus volume (P-V) curve has been advocated as the basis for controlling a ventilator to carry out mechanical ventilation.
    • SUMMARY OF THE INVENTION
  • The P-V curve represents the entire respiratory system and may not adequately reflect the individual air spaces.
  • The invention further recognizes that recruitment continues above the inflection point and may continue at airway pressures beyond 30 cmH2O and that the primary mechanism of lung volume change may be recruitment/de-recruitment (R/D) rather than isotropic and anisotropic alveolar volume change. Lung volume change to 80% of total lung capacity (TLC) may well be a result of alveolar number increase (RID) rather than alveolar size. Furthermore, recruitment is an end inspiratory phenomenon and may be more closely related to plateau pressure rather than PEEP. Therefore, to prevent tidal recruitment/de-recruitment (RID), cyclic shear stress and low volume lung injury, the invention contemplates that higher pressure may be required to achieve complete recruitment. It is recognized that if PEEP levels are set to end inspiratory pressure in order to completely recruit the lung, the superimposition of tidal ventilation could result in over-distension and high volume lung injury despite tidal volume reduction.
  • Accordingly, the invention recognizes that recruitment is an inflation phenomenon which continues beyond conventional PEEP levels. Recruitment requires enough pressure to overcome threshold-opening pressures and the superimposed pressure of the airspace. Plateau pressure or continuous positive airway pressure (CPAP) rather than PEEP level may be more appropriate determinants of full lung recruitment. PEEP conceptually prevents de-recruitment after a sustained inflation. Airway closure or de-recruitment is a deflation phenomenon. Therefore, in accordance with the invention, PEEP may be more suitable set to the inflection point of the deflation limb of the P-V curve rather than that of the inflation limb.
  • Greater hysteresis results from a downward and right displacement of the inflation limb of the P-V curve.
  • Rather than PEEP, plateau or CPAP levels should be utilized for bringing about airway opening (recruitment), allowing substantially complete recruitment. In addition to adequate threshold pressure, complete recruitment requires constant inflation in order to sustain recruitment. Furthermore, sustained recruitment facilitates ventilation on the deflation limb. Ventilation occurs on the deflation limb of the P-V curve only after a sustained recruitment maneuver. Sustained inflation pushes the P-V curve to the outer envelope on to the deflation limb. Stress relaxation accounts for a pressure reduction on the order of 20% within the initial 4 seconds of inflation.
  • In accordance with the invention, APRV mode ventilation is established based on an initial set of ventilation parameters selected as described in further detail below. Once ventilation has been initiated, the parameter, T2, which defines the duration of the ventilator release phase, is monitored and adjusted according to at least one and preferable several alternative methods.
  • One method is to measure the expiratory gas flow rate during expiration and to adjust T2, if necessary, such that T2 is terminated when the rate of expiratory gas flow is at a value of about 25% to 50% of its absolute peak value during expiration. To achieve this, the ventilator is controlled to monitor the expiratory gas flow rate and terminate the release phase when the flow rate reaches a value within the aforementioned range.
  • Another method is to monitor expiratory flow and determine, based on the flow pattern, whether the flow is of a restrictive or obstructive nature, and adjust T2 accordingly. According to yet another method, the expiratory flow is monitored for the presence of an inflection point and T2 is adjusted as required to substantially eliminate or at least reduce the inflection point.
  • In the event of hypercarbia, the highest airway pressure achieved during inspiration (P1) and the duration of the positive pressure phase (T1) are both incrementally increased substantially contemporaneously once or more as needed until blood carbon dioxide declines to an acceptable level.
  • Accordingly to yet another aspect of the invention, weaning from ventilation is carried out by initiating a series of successive reductions in P1, each of which is accompanied by a substantially contemporaneous, increase in the duration of inspiration T1 such that over time, ventilation is transitioned from APRV to a substantially CPAP mode.
  • Applicant's ventilation method and method for controlling a ventilation apparatus based on same provides significant advantages over the prior art. These advantages include an increase in vent free days, lower ventilator-related drug costs, reduced ventilator associated complications, reduced likelihood of high volume lung injury, and reduced likelihood of low volume lung injury. These and other objects and advantages of the invention will become more apparent to a person of ordinary skill in the art in light of the following detailed description and appended drawings.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a flowchart illustrating a preferred embodiment of a ventilation method and control of a ventilator based on same according to the invention;
  • FIG. 2 is a schematic airway pressure versus time tracing for airway pressure release ventilation;
  • FIG. 3 is a airway pressure versus time tracing during the inspiratory (P1) phase of ventilation;
  • FIG. 4 is an airway volume versus pressure curve illustrating a shift from the inspiratory limb to the expiratory limb thereof;
  • FIG. 5 is an inspiratory and expiratory gas flow versus time tracing for airway pressure release ventilation;
  • FIG. 6 is an expiratory gas flow versus time tracing;
  • FIG. 7 is a set of expiratory gas flow versus time tracing illustrating determination of whether flow pattern is normal, restrictive or obstructive based on the shape of the tracing, and
  • FIG. 8 is a set of airway pressure versus time tracings illustrating ventilation weaning by successive reductions in pressure PI and substantially contemporaneous increases in time T1.
    • DETAILED DESCRIPTION
  • An operator interface coupled to the control unit typically includes a graphical user interface as well as a keyboard and/or pointing device to enable an operator to select the operating mode of the ventilator and/or to enter or edit patient data and operating parameters such as the pressures, times, flows, and/or volumes associated with one or more ventilation cycles.
  • Referring to FIG. 1, the invention contemplates initiating ventilation of a patient in an APRV mode based on initial oxygenation and ventilation settings. The airway pressure during expiration (P2) is substantially zero throughout ventilation to allow for the rapid acceleration of expiratory gas flow rates. Typically, the fraction of oxygen in the inspired gas (FiO2) is initially set at about 0.5 to 1.0 (i.e. about 50% to 100%). The highest airway pressure achieved during inspiration (PI) must be sufficiently high to overcome airspace closing forces and initiate recruitment of lung volume. PI may suitably be initialized at a default value of about 35 cmH2O. Alternatively, PI may be established based either on the severity and type of lung injury or based on recruitment pressure requirements. The latter method is preferred in cases where the ventilation/perfusion ratio is less than or equal to about two hundred millimeters of mercury (200 mmHg). The ventilation perfusion ratio is preferably monitored continuously. It is the ratio of the partial pressure of oxygen in the blood of the patient to the fraction of oxygen present in the inspired gas (i.e. PaO2/FiO2 but is commonly abbreviated as P/F).
  • Where the type and severity of lung injury are characterized by a P/F of greater than about 350 mmHg, an initial value of P1 within the range of about 20 cmH2O to 28 cmH2O is preferably established. On the other hand, if the P/F ratio is less than about 350 mmHg, P1 is preferably initialized within the range of about 28 cmH2O to 35 cmH2O.
  • In situations where the P/F ration is less than or equal to about 200 mm Hg, such as may occur where the patient's initial injury is non-pulmonary and/or lung injury is of an indirect nature, the invention contemplates establishment of P1 at a value of between about 35 mmHg and 40 mmHg but preferably not appreciably above 40 mmHg.
  • Initially, the duration of the positive pressure phase (Ti) is established at a value within the range of about 5.0 to about 6.0 seconds unless the measured PaCO2 is greater than about 60 mmHg.
  • Once initial values of P1, P2, T1 and T2 have been established, ventilation continues in a repetitive APRV mode cycle generally as illustrated in FIG. 2. During management of ventilation in accordance with the invention, the initial values of one or more of these parameters are re-assessed and modified in accordance with measured parameters as will now be described with continued reference to FIG. 1.
  • In management of ventilation in accordance with the invention, a principal goal is to maintain the level of carbon dioxide in the blood of the ventilated patient (PaCo2) at a level of less than or equal to about 50 mmHg. Toward that end, arterial PaCO2 is monitored continuously or measured as clinically indicated and the ventilator controlled to adjust ventilation as follows. Any time after ventilation has commenced, but preferably soon thereafter or promptly upon any indication of hypercarbia (PaCO2 above about 50 mmHg), the setting of T2 is optionally but preferably checked and re-adjusted if necessary. According to the invention, optimal end expiratory lung volume is maintained by titration of the duration of the expiration or release phase by terminating T2 based on expiratory gas flow. To do so, the flow rate of the expiratory gas is measured by the ventilator and checked in relation to the time at which the controller of the ventilator initiates termination of the release phase. The expiratory exhaust valve should be actuated to terminate the release phase T2, at a time when the flow rate of the expiratory gas has decreased to about 25% to 50% of its absolute peak expiratory flow rate (PEFR). An example is illustrated in FIG. 5. In that example, T2 (sometimes referred to as Tlow) terminates by controlling the expiratory exhaust valve to terminate the release phase when the expiratory gas flow rate diminishes to 40% PEFR.
  • If monitoring of PaCO2 indicates hypocarbia is present (i.e. PaCO2 less than about 50 mmHg), T1 is increased by about 0.5 seconds while maintaining PI substantially unchanged. Should the patient remain hypocarbic as indicated by subsequent measure of PaCO2, weaning in the manner to be described may be initiated provided oxygenation is satisfactory and weaning is not otherwise contraindicated based on criteria to be described further below.
  • The hypercarbic patient though is not to be weaned. In the event of hypercarbia, the invention contemplates assessment of the expiratory flow pattern before making significant further adjustments to ventilation parameters. This assessment can readily be carried out by a software program stored within the control unit of the ventilator which carries out automated analysis of the expiration flow versus time tracing. As illustrated in FIG. 7, normal expiratory flow is characterized by flow which declines substantially monotonically from the onset of the release phase through its termination and does not fall off prematurely or abruptly. Restrictive flow in contrast declines rapidly from the onset of the release phase to zero or a relatively small value. Obstructive flow tends to be more extended in duration and is characterized by an inflection point beyond which the rate of flow falls off markedly from its initial rate. FIG. 6 illustrates another example of an obstructive flow pattern. Based on analysis of flow data provided by expiratory flow sensors, the control unit of the ventilator is programmed to determine whether flow is obstructive or restrictive based on the characteristics just described. If it is determined that obstructive or restrictive flow is present, the invention contemplates adjusting T2 before making any other significant adjustments to ventilation parameters. This can be done according to either of two alternative methods.
  • One method is to adjust T2 to a predetermined value according to whether flow is either obstructive or restrictive but allowing T2 to remain at its previous value if flow is normal. In the case of restrictive flow, T2 should be adjusted to less than about 0.7 seconds. On the other hand, obstructive flow calls for a T2 of greater duration, preferably greater than about 0.7 seconds with 1.0 to 1.2 being typical.
  • PaCO2 should then be reassessed and concomitant increases of about 0.5 seconds in T1 and about 2 cmH2O in P1 repeated as indicated in FIG. 1 until the patient is no longer hypercarbic.
  • Upon meeting the latter objective, weaning in the manner to be described may be initiated provided the ventilation goal described earlier (i.e. a PaCO2 of less than about 50 mmHg) is met and weaning is not otherwise contraindicated.
  • If such action does not result in raising oxygenation and saturation to at least the goals of about PaO2 of about 80 mmHg and SaO2 of about 95%, P1 is increased to a maximum of about 45 cmH2O and Ti is progressively further increased by about 0.5 seconds to 1.0 seconds.
  • Once those oxygenation and saturation goals are met, ventilation is controlled to maintain those goals while progressively decreasing FiO2 and P1 toward the levels at which initiation of weaning can be considered. More particularly, P1 is decreased by about 1 cmH2O per hour while FiO2 is decreased by about 0.05 about every thirty (30) minutes while maintaining an oxygen saturation of at least about 95%.
  • That is, when PaCO2 remains below about 50 mmHg and SaO2 remains at least about 95% at a P1 of about 35 cmH2O and FiO2, if previously higher, has been weaned to a level of not greater than about 0.5
  • However, during the second stage, the reductions in P1 take place in increments of about 4 cmH2O and the increases in T1 are each about 2.0 seconds.
  • Once the patient is tolerating CPAP at about 5 cmH2O with FiO2 of not greater than about 0.5, the patient's ability to maintain unassisted breathing is assessed, preferably for at least about 2 hours or more.
  • a.) SPO2 of at least about 0.90 and/or PaO2 of at least about 60 mmHg;
  • b.) tidal volume of not less than about 4 ml/kg of ideal bodyweight;
  • c.) respiration rate not significantly above about 35 breaths per minute; and
  • d.) lack of respiratory distress, with such distress being indicated by the presence of any two or more of the following:
      • i) Heart rate greater than 120% of the 0600-hour rate (through less than about 5 minutes above such rate may be considered acceptable)
      • ii) marked use of accessory muscles to assist breathing;
      • iii) thoroco-abdominal paradox;
      • iv) diaphoresis and/or
      • v) marked subjected dyspnea.
  • If there is an indication of respiratory distress, CPAP at an airway pressure of about 10 cmH2O should be resumed and monitoring and reassessment carried out as needed. However, if criteria a) through d) above are all satisfied, the patient may be transitioned to substantially unassisted breathing such as by extubation with face mask, nasal prong oxygen or room air, T-tube breathing, tracheotomy mask breathing or use of high flow CPAP at about 5 cmH2O.
  • During all phases of ventilation including initiation, management and weaning, the patent should be reassessed at least about every two hours and more frequently if indicated. Blood gas measurements (PaO2 and SaO2 and PCO2) on which govern control of ventilation according to the invention should be monitored not less frequently than every two hours though substantially continuous monitoring of all parameters would be considered ideal. Blood gas measurements (PaO2 and SaO2 and PaCO2) that govern control of ventilation according to the invention should be monitored not less frequently than every two hours though substantially continuous monitoring of all parameters would be considered ideal.
  • Just prior to and during weaning at least one special assessment should be conducted daily, preferably between 0600 and 1000 hours. If not possible to do so, a delay of not more than about four hours could be tolerated. Weaning should not be initiated or continued further unless:
  • a) at least about 12 hours have passed since initial ventilation settings were established or first changed,
  • b) the patient is not receiving neuromuscular blocking agents and is without neuromuscular blockade, and
  • c) Systolic arterial pressure is at least about 90 mmHg without vasopressors (other than “renal” dose dopamine).
  • If these criteria are all met, a trial should be conducted by ventilating the patent in CPAP mode at about 5 cmH2O and an FiO2 of about 0.5 for about five (5) minutes. If the respiration rate of the patient does not exceed about 35 breaths per minute (bpm) during the five (5) minute period weaning as described above may proceed. However, if during the five (5) minute period the respiration rate exceeds about 35 bpm it should be determined whether such tachypnea is associated with anxiety. If so, administer appropriate treatment for the anxiety and repeat the trial within about four (4) hours. If tachypnea does not appear to be associated with anxiety, resume management of ventilation at the parameter settings in effect prior to the trial and resume management of ventilation as described above. Re-assess at least daily until weaning as described above can be initiated.

Claims (9)

1-14. (canceled)
15. A method of weaning from ventilation comprising the step of substantially contemporaneously adjusting a high airway pressure (P1) and a high time (T1).
16. The method of claim 15, wherein the adjusting step comprises decreasing P1 and increasing T1.
17. The method of claim 16, wherein P1 is decreased at a rate of about 2 cmH2O per hour and T1 is increased by about 0.5 to 1.0 s substantially contemporaneously with each decrease in P1.
18. The method of claim 16, wherein P1 is decreased in increments of about 4 cmH2O and T1 is increased in increments of about 2 s.
19. The method of claim 16, further comprising the step of transitioning ventilation from a preset continuous positive airway pressure (CPAP) level mode with an intermittent release to a substantially continuous positive airway pressure (CPAP) mode.
20. The method of claim 16, further comprising the step of transitioning ventilation from a preset continuous positive airway pressure (CPAP) level mode with an intermittent release to a substantially continuous positive airway pressure (CPAP) mode with automatic tube compensation (ATC).
21. The method of claim 19, further comprising the steps of:
a) monitoring blood oxygen levels,
b) monitoring blood carbon dioxide levels,
c) determining the ratio of spontaneous minute ventilation to machine minute ventilation, and
d) determining the level of sedation.
22. The method of claim 19, further comprising the steps of substantially simultaneously decreasing machine minute ventilation and increasing spontaneous minute ventilation to transition from the CPAP mode to an unassisted breathing mode.
US11/386,807 2001-06-21 2006-03-23 Ventilation method and control of a ventilator based on same Abandoned US20060174884A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/386,807 US20060174884A1 (en) 2001-06-21 2006-03-23 Ventilation method and control of a ventilator based on same
US14/820,308 US20150359983A1 (en) 2001-06-21 2015-08-06 Ventilation method and control of a ventilator based on same
US15/648,419 US20180154096A1 (en) 2001-06-21 2017-07-12 Ventilation method and control of a ventilator based on same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29992801P 2001-06-21 2001-06-21
US10/176,710 US7246618B2 (en) 2001-06-21 2002-06-20 Ventilation method and control of a ventilator based on same
US11/386,807 US20060174884A1 (en) 2001-06-21 2006-03-23 Ventilation method and control of a ventilator based on same

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/176,710 Division US7246618B2 (en) 2001-06-21 2002-06-20 Ventilation method and control of a ventilator based on same

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/820,308 Continuation US20150359983A1 (en) 2001-06-21 2015-08-06 Ventilation method and control of a ventilator based on same
US15/648,419 Continuation US20180154096A1 (en) 2001-06-21 2017-07-12 Ventilation method and control of a ventilator based on same

Publications (1)

Publication Number Publication Date
US20060174884A1 true US20060174884A1 (en) 2006-08-10

Family

ID=26872514

Family Applications (5)

Application Number Title Priority Date Filing Date
US10/176,710 Expired - Lifetime US7246618B2 (en) 2001-06-21 2002-06-20 Ventilation method and control of a ventilator based on same
US11/386,807 Abandoned US20060174884A1 (en) 2001-06-21 2006-03-23 Ventilation method and control of a ventilator based on same
US11/878,295 Expired - Lifetime US8573205B2 (en) 2001-06-21 2007-07-23 Ventilation method and control of a ventilator based on same
US14/820,308 Abandoned US20150359983A1 (en) 2001-06-21 2015-08-06 Ventilation method and control of a ventilator based on same
US15/648,419 Abandoned US20180154096A1 (en) 2001-06-21 2017-07-12 Ventilation method and control of a ventilator based on same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/176,710 Expired - Lifetime US7246618B2 (en) 2001-06-21 2002-06-20 Ventilation method and control of a ventilator based on same

Family Applications After (3)

Application Number Title Priority Date Filing Date
US11/878,295 Expired - Lifetime US8573205B2 (en) 2001-06-21 2007-07-23 Ventilation method and control of a ventilator based on same
US14/820,308 Abandoned US20150359983A1 (en) 2001-06-21 2015-08-06 Ventilation method and control of a ventilator based on same
US15/648,419 Abandoned US20180154096A1 (en) 2001-06-21 2017-07-12 Ventilation method and control of a ventilator based on same

Country Status (1)

Country Link
US (5) US7246618B2 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007026036B3 (en) * 2007-06-04 2008-03-27 Dräger Medical AG & Co. KG Operation of a respiratory and/or anesthetic system matches the actual and set portion of the peak expiratory flow
DE102007026035B3 (en) * 2007-06-04 2008-03-27 Dräger Medical AG & Co. KG Operating breathing and/or anaesthetizing apparatus in APRV mode involves detecting spontaneous expiration effort, initiating pressure release phase if detected spontaneous expiration effort occurs in predefined trigger window
US20080072896A1 (en) * 2006-09-27 2008-03-27 Nellcor Puritan Bennett Incorporated Multi-Level User Interface for a Breathing Assistance System
US20080072902A1 (en) * 2006-09-27 2008-03-27 Nellcor Puritan Bennett Incorporated Preset breath delivery therapies for a breathing assistance system
US20080295839A1 (en) * 2007-06-01 2008-12-04 Habashi Nader M Ventilator Apparatus and System of Ventilation
US20090114222A1 (en) * 2007-11-02 2009-05-07 Drager Medical Ag & Co. Kg Process for operating a respirator or anesthesia device in the aprv mode taking into account the impedance and/or the impedance change
US20090205663A1 (en) * 2008-02-19 2009-08-20 Nellcor Puritan Bennett Llc Configuring the operation of an alternating pressure ventilation mode
US20100288283A1 (en) * 2009-05-15 2010-11-18 Nellcor Puritan Bennett Llc Dynamic adjustment of tube compensation factor based on internal changes in breathing tube
USD638852S1 (en) 2009-12-04 2011-05-31 Nellcor Puritan Bennett Llc Ventilator display screen with an alarm icon
US8001967B2 (en) 1997-03-14 2011-08-23 Nellcor Puritan Bennett Llc Ventilator breath display and graphic user interface
US8021310B2 (en) 2006-04-21 2011-09-20 Nellcor Puritan Bennett Llc Work of breathing display for a ventilation system
USD649157S1 (en) 2009-12-04 2011-11-22 Nellcor Puritan Bennett Llc Ventilator display screen with a user interface
US8335992B2 (en) 2009-12-04 2012-12-18 Nellcor Puritan Bennett Llc Visual indication of settings changes on a ventilator graphical user interface
US8443294B2 (en) 2009-12-18 2013-05-14 Covidien Lp Visual indication of alarms on a ventilator graphical user interface
US8453645B2 (en) 2006-09-26 2013-06-04 Covidien Lp Three-dimensional waveform display for a breathing assistance system
US8776792B2 (en) 2011-04-29 2014-07-15 Covidien Lp Methods and systems for volume-targeted minimum pressure-control ventilation
US8783250B2 (en) 2011-02-27 2014-07-22 Covidien Lp Methods and systems for transitory ventilation support
US8794234B2 (en) 2008-09-25 2014-08-05 Covidien Lp Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators
US8924878B2 (en) 2009-12-04 2014-12-30 Covidien Lp Display and access to settings on a ventilator graphical user interface
US9119925B2 (en) 2009-12-04 2015-09-01 Covidien Lp Quick initiation of respiratory support via a ventilator user interface
US9262588B2 (en) 2009-12-18 2016-02-16 Covidien Lp Display of respiratory data graphs on a ventilator graphical user interface
US9327089B2 (en) 2012-03-30 2016-05-03 Covidien Lp Methods and systems for compensation of tubing related loss effects
US9358355B2 (en) 2013-03-11 2016-06-07 Covidien Lp Methods and systems for managing a patient move
US9375542B2 (en) 2012-11-08 2016-06-28 Covidien Lp Systems and methods for monitoring, managing, and/or preventing fatigue during ventilation
CN106975134A (en) * 2017-04-11 2017-07-25 湖南明康中锦医疗科技发展有限公司 Method and device for adjusting replacement point of respirator and noninvasive respirator
US9950129B2 (en) 2014-10-27 2018-04-24 Covidien Lp Ventilation triggering using change-point detection
US9993604B2 (en) 2012-04-27 2018-06-12 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US10362967B2 (en) 2012-07-09 2019-07-30 Covidien Lp Systems and methods for missed breath detection and indication
US10668239B2 (en) 2017-11-14 2020-06-02 Covidien Lp Systems and methods for drive pressure spontaneous ventilation
US11517691B2 (en) 2018-09-07 2022-12-06 Covidien Lp Methods and systems for high pressure controlled ventilation
US11672934B2 (en) 2020-05-12 2023-06-13 Covidien Lp Remote ventilator adjustment

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7246618B2 (en) * 2001-06-21 2007-07-24 Nader Maher Habashi Ventilation method and control of a ventilator based on same
WO2004075746A2 (en) 2003-02-27 2004-09-10 Cardiodigital Limited Method and system for analysing and processing ph0t0plethysmogram signals using wavelet transform
WO2005050525A1 (en) 2003-11-12 2005-06-02 Draeger Medical Systems, Inc. A healthcare processing device and display system
US7802571B2 (en) 2003-11-21 2010-09-28 Tehrani Fleur T Method and apparatus for controlling a ventilator
DE102004019122A1 (en) * 2004-04-16 2005-11-10 Universitätsklinikum Freiburg Method for controlling a ventilator and installation therefor
US9468398B2 (en) * 2004-06-24 2016-10-18 Convergent Engineering, Inc. Method and apparatus for detecting and quantifying intrinsic positive end-expiratory pressure
US20070077200A1 (en) * 2005-09-30 2007-04-05 Baker Clark R Method and system for controlled maintenance of hypoxia for therapeutic or diagnostic purposes
US7918223B2 (en) * 2005-11-09 2011-04-05 Carefusion 207, Inc. System and method for circuit compliance compensated pressure-regulated volume control in a patient respiratory ventilator
WO2007085110A1 (en) * 2006-01-30 2007-08-02 Hamilton Medical Ag O2-controller
US8728059B2 (en) 2006-09-29 2014-05-20 Covidien Lp System and method for assuring validity of monitoring parameter in combination with a therapeutic device
EP2091429B1 (en) * 2006-11-16 2010-11-10 Hamilton Medical AG Method and device for determining the peep during the respiration of a patient
US8695593B2 (en) * 2007-03-31 2014-04-15 Fleur T. Tehrani Weaning and decision support system for mechanical ventilation
WO2008148134A1 (en) * 2007-06-01 2008-12-04 Intensive Care On-Line Network, Inc. Ventilator apparatus and system for ventilation
EP2249700B1 (en) * 2008-02-07 2019-04-24 Koninklijke Philips N.V. Apparatus for measuring and predicting patients' respiratory stability
WO2009120639A2 (en) * 2008-03-27 2009-10-01 Nellcor Puritan Bennett Llc Breathing assistance systems with lung recruitment maneuvers
EP2363163A1 (en) * 2008-03-27 2011-09-07 Nellcor Puritan Bennett LLC Device for controlled delivery of breathing gas to a patient using multiple ventilation parameters
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
US20090326402A1 (en) * 2008-06-30 2009-12-31 Nellcor Puritan Bennett Ireland Systems and methods for determining effort
US8398555B2 (en) * 2008-09-10 2013-03-19 Covidien Lp System and method for detecting ventilatory instability
US8424520B2 (en) 2008-09-23 2013-04-23 Covidien Lp Safe standby mode for ventilator
US8302602B2 (en) 2008-09-30 2012-11-06 Nellcor Puritan Bennett Llc Breathing assistance system with multiple pressure sensors
US9011347B2 (en) 2008-10-03 2015-04-21 Nellcor Puritan Bennett Ireland Methods and apparatus for determining breathing effort characteristics measures
US9155493B2 (en) 2008-10-03 2015-10-13 Nellcor Puritan Bennett Ireland Methods and apparatus for calibrating respiratory effort from photoplethysmograph signals
CN102245242B (en) * 2008-12-10 2015-06-24 皇家飞利浦电子股份有限公司 Airway pressure release ventilation
WO2010088610A2 (en) 2009-01-31 2010-08-05 Mayo Foundation For Medical Education And Research Presentation of critical patient data
CN102333559B (en) * 2009-02-25 2015-02-25 皇家飞利浦电子股份有限公司 Pressure support system with machine delivered breaths
US10426906B2 (en) 2009-03-18 2019-10-01 Mayo Foundation For Medical Education And Research Ventilator monitoring and control
ES2371045T3 (en) * 2009-05-29 2011-12-26 Fluida Respi METHOD FOR DETERMINING TREATMENTS USING SPECIFIC PULMONARY PATIENT MODELS AND COMPUTER METHODS.
US8444570B2 (en) * 2009-06-09 2013-05-21 Nellcor Puritan Bennett Ireland Signal processing techniques for aiding the interpretation of respiration signals
US20100331716A1 (en) * 2009-06-26 2010-12-30 Nellcor Puritan Bennett Ireland Methods and apparatus for measuring respiratory function using an effort signal
US20100331715A1 (en) * 2009-06-30 2010-12-30 Nellcor Puritan Bennett Ireland Systems and methods for detecting effort events
EP2453966B1 (en) * 2009-07-14 2019-03-20 ResMed Ltd. Setup automation for respiratory treatment apparatus
US8755854B2 (en) 2009-07-31 2014-06-17 Nellcor Puritan Bennett Ireland Methods and apparatus for producing and using lightly filtered photoplethysmograph signals
US20110023878A1 (en) * 2009-07-31 2011-02-03 Nellcor Puritan Bennett Llc Method And System For Delivering A Single-Breath, Low Flow Recruitment Maneuver
US20110023881A1 (en) * 2009-07-31 2011-02-03 Nellcor Puritan Bennett Llc Method And System For Generating A Pressure Volume Loop Of A Low Flow Recruitment Maneuver
US8596270B2 (en) * 2009-08-20 2013-12-03 Covidien Lp Systems and methods for controlling a ventilator
US8439036B2 (en) 2009-12-01 2013-05-14 Covidien Lp Exhalation valve assembly with integral flow sensor
US8469031B2 (en) 2009-12-01 2013-06-25 Covidien Lp Exhalation valve assembly with integrated filter
US8439037B2 (en) 2009-12-01 2013-05-14 Covidien Lp Exhalation valve assembly with integrated filter and flow sensor
US8469030B2 (en) 2009-12-01 2013-06-25 Covidien Lp Exhalation valve assembly with selectable contagious/non-contagious latch
US20110138311A1 (en) * 2009-12-04 2011-06-09 Nellcor Puritan Bennett Llc Display Of Respiratory Data On A Ventilator Graphical User Interface
US20110138323A1 (en) * 2009-12-04 2011-06-09 Nellcor Puritan Bennett Llc Visual Indication Of Alarms On A Ventilator Graphical User Interface
USD655809S1 (en) 2010-04-27 2012-03-13 Nellcor Puritan Bennett Llc Valve body with integral flow meter for an exhalation module
USD655405S1 (en) 2010-04-27 2012-03-06 Nellcor Puritan Bennett Llc Filter and valve body for an exhalation module
USD653749S1 (en) 2010-04-27 2012-02-07 Nellcor Puritan Bennett Llc Exhalation module filter body
US8834378B2 (en) 2010-07-30 2014-09-16 Nellcor Puritan Bennett Ireland Systems and methods for determining respiratory effort
US9656040B2 (en) * 2010-12-21 2017-05-23 Koninklijke Philips N.V. Active valve for ventilators
US9629971B2 (en) 2011-04-29 2017-04-25 Covidien Lp Methods and systems for exhalation control and trajectory optimization
US8801619B2 (en) 2011-06-30 2014-08-12 Covidien Lp Photoplethysmography for determining ventilation weaning readiness
US9364624B2 (en) 2011-12-07 2016-06-14 Covidien Lp Methods and systems for adaptive base flow
US9498589B2 (en) 2011-12-31 2016-11-22 Covidien Lp Methods and systems for adaptive base flow and leak compensation
US9022031B2 (en) 2012-01-31 2015-05-05 Covidien Lp Using estimated carinal pressure for feedback control of carinal pressure during ventilation
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer
US8844526B2 (en) 2012-03-30 2014-09-30 Covidien Lp Methods and systems for triggering with unknown base flow
US9492629B2 (en) 2013-02-14 2016-11-15 Covidien Lp Methods and systems for ventilation with unknown exhalation flow and exhalation pressure
US9981096B2 (en) 2013-03-13 2018-05-29 Covidien Lp Methods and systems for triggering with unknown inspiratory flow
US9950135B2 (en) 2013-03-15 2018-04-24 Covidien Lp Maintaining an exhalation valve sensor assembly
US10518050B2 (en) * 2013-06-11 2019-12-31 Koninklijke Philips N.V. Synchronous airway pressure release ventilation
US10022068B2 (en) 2013-10-28 2018-07-17 Covidien Lp Systems and methods for detecting held breath events
US10183139B2 (en) 2014-04-11 2019-01-22 Vyaire Medical Capital Llc Methods for controlling mechanical lung ventilation
US9956365B2 (en) * 2014-04-11 2018-05-01 Vyaire Medical Capital Llc Lung ventilation apparatus
US9839760B2 (en) 2014-04-11 2017-12-12 Vyaire Medical Capital Llc Methods for controlling mechanical lung ventilation
US10279137B1 (en) 2014-06-27 2019-05-07 Orlando Morejon Connector assembly for a medical ventilator system
US11395897B1 (en) 2014-06-27 2022-07-26 Orlando Morejon Connector assembly for a medical ventilator system
US9925346B2 (en) 2015-01-20 2018-03-27 Covidien Lp Systems and methods for ventilation with unknown exhalation flow
SE538864C2 (en) * 2015-05-25 2017-01-10 The Lung Barometry Sweden AB Method System and Software for Protective Ventilation
US10589045B2 (en) * 2016-10-12 2020-03-17 Board Of Regents Of The University Of Texas System Smart oxygenation system employing automatic control using SpO2-to-FiO2 ratio
US11478595B2 (en) 2016-11-02 2022-10-25 Fisher & Paykel Healthcare Limited Method of driving a form of respiratory therapy
US10835177B2 (en) * 2017-06-02 2020-11-17 General Electric Company Anesthesia assessment system and method for lung protective ventilation
US11478594B2 (en) 2018-05-14 2022-10-25 Covidien Lp Systems and methods for respiratory effort detection utilizing signal distortion
US11298484B2 (en) * 2018-05-14 2022-04-12 General Electric Company Method and systems for executing nasal high flow therapy with settings determined from flow outputs during a previous ventilation mode
US11752287B2 (en) 2018-10-03 2023-09-12 Covidien Lp Systems and methods for automatic cycling or cycling detection
US11612706B2 (en) * 2019-11-25 2023-03-28 John C. Taube Methods, systems, and devices for controlling mechanical ventilation
DE102021000313A1 (en) * 2020-02-06 2021-08-12 Löwenstein Medical Technology S.A. Method for operating a ventilator for artificial ventilation of a patient and such a ventilator
WO2021189198A1 (en) * 2020-03-23 2021-09-30 深圳迈瑞生物医疗电子股份有限公司 Method and apparatus for monitoring ventilation of patient
EP4000673B1 (en) * 2020-11-24 2024-06-12 Löwenstein Medical Technology S.A. Device for specifying a cpap respirator having a minimum volume
CN117642201A (en) * 2021-09-29 2024-03-01 深圳迈瑞生物医疗电子股份有限公司 Medical ventilation equipment and ventilation control method

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2690178A (en) * 1950-11-13 1954-09-28 Research Corp Automatic apparatus for administering drugs
US2690175A (en) * 1952-11-08 1954-09-28 William W Daughtry Traction table
US2754819A (en) * 1953-06-29 1956-07-17 Harry M Kirschbaum Apparatus for automatically administering anesthetics
US3734091A (en) * 1971-06-22 1973-05-22 Airco Inc Oxygen control system with blood oxygen saturation sensing means and method for closed system breathing
US3741208A (en) * 1971-02-23 1973-06-26 B Jonsson Lung ventilator
US3946729A (en) * 1974-10-17 1976-03-30 Hewlett-Packard Company Ventilator patient monitor
US4036221A (en) * 1972-05-01 1977-07-19 Sutter Hospitals Medical Research Foundation Respirator
US4121578A (en) * 1976-10-04 1978-10-24 The Bendix Corporation Physiological responsive control for an oxygen regulator
US4163450A (en) * 1977-01-27 1979-08-07 Cramp Harvey E Method and apparatus for weaning patient from continuous mechanical ventilation
US4206754A (en) * 1976-06-02 1980-06-10 Boc Limited Lung ventilators
US4281651A (en) * 1977-05-06 1981-08-04 Airco, Inc. Lung ventilator
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4323064A (en) * 1976-10-26 1982-04-06 Puritan-Bennett Corporation Volume ventilator
US4326513A (en) * 1979-07-02 1982-04-27 Dragerwerk Ag Patient data controlled respiration system
US4773411A (en) * 1986-05-08 1988-09-27 Downs John B Method and apparatus for ventilatory therapy
US5097424A (en) * 1986-12-31 1992-03-17 Elmed Genevri Srl Constant flow and controlled ventilation, pressure responsive pulmotor
US5103814A (en) * 1988-04-28 1992-04-14 Timothy Maher Self-compensating patient respirator
US5107830A (en) * 1987-02-21 1992-04-28 University Of Manitoba Lung ventilator device
US5186167A (en) * 1990-10-31 1993-02-16 The United States Of America As Represented By The Department Of Health And Human Services Catheter tip for intratracheal ventilation and intratracheal pulmonary ventilation
US5255675A (en) * 1990-10-31 1993-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Device for intratracheal ventilation and intratracheal pulmonary ventilation
US5388575A (en) * 1992-09-25 1995-02-14 Taube; John C. Adaptive controller for automatic ventilators
US5390666A (en) * 1990-05-11 1995-02-21 Puritan-Bennett Corporation System and method for flow triggering of breath supported ventilation
US5582163A (en) * 1993-12-06 1996-12-10 Intermed Equipamento Medico Hospitalar Ltda. Respiratory control system and apparatus
US5596981A (en) * 1993-07-19 1997-01-28 Soucy; Paul B. Solar device and method for assembly
US5632270A (en) * 1994-09-12 1997-05-27 Puritan-Bennett Corporation Method and apparatus for control of lung ventilator exhalation circuit
US5884622A (en) * 1996-12-20 1999-03-23 University Of Manitoba Automatic determination of passive elastic and resistive properties of the respiratory system during assisted mechanical ventilation
US5909731A (en) * 1994-09-12 1999-06-08 Puritan-Bennett Corporation Lung ventilator safety circuit
US6165151A (en) * 1996-09-03 2000-12-26 Weiner; Daniel L. Apparatus and methods for control of intravenous sedation
US6463930B2 (en) * 1995-12-08 2002-10-15 James W. Biondi System for automatically weaning a patient from a ventilator, and method thereof
US6532960B1 (en) * 2000-07-10 2003-03-18 Respironics, Inc. Automatic rise time adjustment for bi-level pressure support system
US6609517B1 (en) * 1994-06-03 2003-08-26 Respironics, Inc. Method and apparatus for providing positive airway pressure to a patient
US6679258B1 (en) * 1998-08-25 2004-01-20 Siemens Elema Ab Ventilator operable in a compensated volume support mode
US7246618B2 (en) * 2001-06-21 2007-07-24 Nader Maher Habashi Ventilation method and control of a ventilator based on same
US20080295839A1 (en) * 2007-06-01 2008-12-04 Habashi Nader M Ventilator Apparatus and System of Ventilation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US559698A (en) * 1896-05-05 Bicycle rest or support
US5107831A (en) * 1989-06-19 1992-04-28 Bear Medical Systems, Inc. Ventilator control system using sensed inspiratory flow rate
DE4221931C1 (en) * 1992-07-03 1993-07-08 Harald Dr. 8521 Moehrendorf De Mang
SE9502543D0 (en) * 1995-07-10 1995-07-10 Lachmann Burkhardt Artificial ventilation system
US5937854A (en) * 1998-01-06 1999-08-17 Sensormedics Corporation Ventilator pressure optimization method and apparatus

Patent Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2690178A (en) * 1950-11-13 1954-09-28 Research Corp Automatic apparatus for administering drugs
US2690175A (en) * 1952-11-08 1954-09-28 William W Daughtry Traction table
US2754819A (en) * 1953-06-29 1956-07-17 Harry M Kirschbaum Apparatus for automatically administering anesthetics
US3741208A (en) * 1971-02-23 1973-06-26 B Jonsson Lung ventilator
US3734091A (en) * 1971-06-22 1973-05-22 Airco Inc Oxygen control system with blood oxygen saturation sensing means and method for closed system breathing
US4036221A (en) * 1972-05-01 1977-07-19 Sutter Hospitals Medical Research Foundation Respirator
US3946729A (en) * 1974-10-17 1976-03-30 Hewlett-Packard Company Ventilator patient monitor
US4206754A (en) * 1976-06-02 1980-06-10 Boc Limited Lung ventilators
US4121578A (en) * 1976-10-04 1978-10-24 The Bendix Corporation Physiological responsive control for an oxygen regulator
US4323064A (en) * 1976-10-26 1982-04-06 Puritan-Bennett Corporation Volume ventilator
US4163450A (en) * 1977-01-27 1979-08-07 Cramp Harvey E Method and apparatus for weaning patient from continuous mechanical ventilation
US4281651A (en) * 1977-05-06 1981-08-04 Airco, Inc. Lung ventilator
US4326513A (en) * 1979-07-02 1982-04-27 Dragerwerk Ag Patient data controlled respiration system
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4773411A (en) * 1986-05-08 1988-09-27 Downs John B Method and apparatus for ventilatory therapy
US5097424A (en) * 1986-12-31 1992-03-17 Elmed Genevri Srl Constant flow and controlled ventilation, pressure responsive pulmotor
US5107830A (en) * 1987-02-21 1992-04-28 University Of Manitoba Lung ventilator device
US5103814A (en) * 1988-04-28 1992-04-14 Timothy Maher Self-compensating patient respirator
US5390666A (en) * 1990-05-11 1995-02-21 Puritan-Bennett Corporation System and method for flow triggering of breath supported ventilation
US5186167A (en) * 1990-10-31 1993-02-16 The United States Of America As Represented By The Department Of Health And Human Services Catheter tip for intratracheal ventilation and intratracheal pulmonary ventilation
US5255675A (en) * 1990-10-31 1993-10-26 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Device for intratracheal ventilation and intratracheal pulmonary ventilation
US5388575A (en) * 1992-09-25 1995-02-14 Taube; John C. Adaptive controller for automatic ventilators
US5596981A (en) * 1993-07-19 1997-01-28 Soucy; Paul B. Solar device and method for assembly
US5582163A (en) * 1993-12-06 1996-12-10 Intermed Equipamento Medico Hospitalar Ltda. Respiratory control system and apparatus
US6609517B1 (en) * 1994-06-03 2003-08-26 Respironics, Inc. Method and apparatus for providing positive airway pressure to a patient
US5909731A (en) * 1994-09-12 1999-06-08 Puritan-Bennett Corporation Lung ventilator safety circuit
US5632270A (en) * 1994-09-12 1997-05-27 Puritan-Bennett Corporation Method and apparatus for control of lung ventilator exhalation circuit
US6463930B2 (en) * 1995-12-08 2002-10-15 James W. Biondi System for automatically weaning a patient from a ventilator, and method thereof
US6165151A (en) * 1996-09-03 2000-12-26 Weiner; Daniel L. Apparatus and methods for control of intravenous sedation
US5884622A (en) * 1996-12-20 1999-03-23 University Of Manitoba Automatic determination of passive elastic and resistive properties of the respiratory system during assisted mechanical ventilation
US6679258B1 (en) * 1998-08-25 2004-01-20 Siemens Elema Ab Ventilator operable in a compensated volume support mode
US6532960B1 (en) * 2000-07-10 2003-03-18 Respironics, Inc. Automatic rise time adjustment for bi-level pressure support system
US7246618B2 (en) * 2001-06-21 2007-07-24 Nader Maher Habashi Ventilation method and control of a ventilator based on same
US20080295839A1 (en) * 2007-06-01 2008-12-04 Habashi Nader M Ventilator Apparatus and System of Ventilation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Esteban et al., A Comparison of Four Methods of Weaning Patients From Mechanical Ventilation, 2/9/95, Massachusetts Medical Society, The New England Journal of Medicine Vol. 332 pages 345-350 *

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8555882B2 (en) 1997-03-14 2013-10-15 Covidien Lp Ventilator breath display and graphic user interface
US8001967B2 (en) 1997-03-14 2011-08-23 Nellcor Puritan Bennett Llc Ventilator breath display and graphic user interface
US8555881B2 (en) 1997-03-14 2013-10-15 Covidien Lp Ventilator breath display and graphic interface
US8597198B2 (en) 2006-04-21 2013-12-03 Covidien Lp Work of breathing display for a ventilation system
US8021310B2 (en) 2006-04-21 2011-09-20 Nellcor Puritan Bennett Llc Work of breathing display for a ventilation system
US10582880B2 (en) 2006-04-21 2020-03-10 Covidien Lp Work of breathing display for a ventilation system
US8453645B2 (en) 2006-09-26 2013-06-04 Covidien Lp Three-dimensional waveform display for a breathing assistance system
US20080072902A1 (en) * 2006-09-27 2008-03-27 Nellcor Puritan Bennett Incorporated Preset breath delivery therapies for a breathing assistance system
US20080072896A1 (en) * 2006-09-27 2008-03-27 Nellcor Puritan Bennett Incorporated Multi-Level User Interface for a Breathing Assistance System
US20080295839A1 (en) * 2007-06-01 2008-12-04 Habashi Nader M Ventilator Apparatus and System of Ventilation
US20080295838A1 (en) * 2007-06-04 2008-12-04 Drager Medical Ag & Co. Kg Process for operating a respirator and/or anesthesia device and a device operated correspondingly
US20080295840A1 (en) * 2007-06-04 2008-12-04 Drager Medical Ag & Co. Kg Process for operating a respirator and/or anesthesia device in the aprv mode with the %pef criterion and a device operated correspondingly
US8695597B2 (en) * 2007-06-04 2014-04-15 Dräger Medical GmbH Process for operating a respirator and/or anesthesia device in the APRV mode with the %PEF criterion and a device operated correspondingly
US9649457B2 (en) 2007-06-04 2017-05-16 Drägerwerk AG & Co. KGaA Process for operating a respirator and/or anesthesia device and a device operated correspondingly
DE102007026036B3 (en) * 2007-06-04 2008-03-27 Dräger Medical AG & Co. KG Operation of a respiratory and/or anesthetic system matches the actual and set portion of the peak expiratory flow
DE102007026035B3 (en) * 2007-06-04 2008-03-27 Dräger Medical AG & Co. KG Operating breathing and/or anaesthetizing apparatus in APRV mode involves detecting spontaneous expiration effort, initiating pressure release phase if detected spontaneous expiration effort occurs in predefined trigger window
US9981095B2 (en) 2007-11-02 2018-05-29 Drägerwerk AG & Co. KGaA Process for operating a respirator or anesthesia device in the APRV mode taking into the impedance and/or the impedance change
DE102007052472B4 (en) 2007-11-02 2020-07-09 Drägerwerk AG & Co. KGaA Method for operating a ventilation and / or anesthesia device in APRV mode taking into account the impedance and / or the change in impedance
DE102007052472A1 (en) 2007-11-02 2009-05-14 Dräger Medical AG & Co. KG Method for operating a ventilation and / or anesthesia device in APRV mode taking into account the impedance and / or the impedance change
US20090114222A1 (en) * 2007-11-02 2009-05-07 Drager Medical Ag & Co. Kg Process for operating a respirator or anesthesia device in the aprv mode taking into account the impedance and/or the impedance change
US20090205663A1 (en) * 2008-02-19 2009-08-20 Nellcor Puritan Bennett Llc Configuring the operation of an alternating pressure ventilation mode
US8794234B2 (en) 2008-09-25 2014-08-05 Covidien Lp Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators
US20100288283A1 (en) * 2009-05-15 2010-11-18 Nellcor Puritan Bennett Llc Dynamic adjustment of tube compensation factor based on internal changes in breathing tube
US8924878B2 (en) 2009-12-04 2014-12-30 Covidien Lp Display and access to settings on a ventilator graphical user interface
USD638852S1 (en) 2009-12-04 2011-05-31 Nellcor Puritan Bennett Llc Ventilator display screen with an alarm icon
US8335992B2 (en) 2009-12-04 2012-12-18 Nellcor Puritan Bennett Llc Visual indication of settings changes on a ventilator graphical user interface
USD649157S1 (en) 2009-12-04 2011-11-22 Nellcor Puritan Bennett Llc Ventilator display screen with a user interface
US9119925B2 (en) 2009-12-04 2015-09-01 Covidien Lp Quick initiation of respiratory support via a ventilator user interface
US9262588B2 (en) 2009-12-18 2016-02-16 Covidien Lp Display of respiratory data graphs on a ventilator graphical user interface
US8443294B2 (en) 2009-12-18 2013-05-14 Covidien Lp Visual indication of alarms on a ventilator graphical user interface
US8499252B2 (en) 2009-12-18 2013-07-30 Covidien Lp Display of respiratory data graphs on a ventilator graphical user interface
US8783250B2 (en) 2011-02-27 2014-07-22 Covidien Lp Methods and systems for transitory ventilation support
US8776792B2 (en) 2011-04-29 2014-07-15 Covidien Lp Methods and systems for volume-targeted minimum pressure-control ventilation
US9327089B2 (en) 2012-03-30 2016-05-03 Covidien Lp Methods and systems for compensation of tubing related loss effects
US10806879B2 (en) 2012-04-27 2020-10-20 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US9993604B2 (en) 2012-04-27 2018-06-12 Covidien Lp Methods and systems for an optimized proportional assist ventilation
US11642042B2 (en) 2012-07-09 2023-05-09 Covidien Lp Systems and methods for missed breath detection and indication
US10362967B2 (en) 2012-07-09 2019-07-30 Covidien Lp Systems and methods for missed breath detection and indication
US10543326B2 (en) 2012-11-08 2020-01-28 Covidien Lp Systems and methods for monitoring, managing, and preventing fatigue during ventilation
US9375542B2 (en) 2012-11-08 2016-06-28 Covidien Lp Systems and methods for monitoring, managing, and/or preventing fatigue during ventilation
US11229759B2 (en) 2012-11-08 2022-01-25 Covidien Lp Systems and methods for monitoring, managing, and preventing fatigue during ventilation
US11559641B2 (en) 2013-03-11 2023-01-24 Covidien Lp Methods and systems for managing a patient move
US10639441B2 (en) 2013-03-11 2020-05-05 Covidien Lp Methods and systems for managing a patient move
US9358355B2 (en) 2013-03-11 2016-06-07 Covidien Lp Methods and systems for managing a patient move
US11712174B2 (en) 2014-10-27 2023-08-01 Covidien Lp Ventilation triggering
US9950129B2 (en) 2014-10-27 2018-04-24 Covidien Lp Ventilation triggering using change-point detection
US10940281B2 (en) 2014-10-27 2021-03-09 Covidien Lp Ventilation triggering
CN106975134A (en) * 2017-04-11 2017-07-25 湖南明康中锦医疗科技发展有限公司 Method and device for adjusting replacement point of respirator and noninvasive respirator
US11559643B2 (en) 2017-11-14 2023-01-24 Covidien Lp Systems and methods for ventilation of patients
US10668239B2 (en) 2017-11-14 2020-06-02 Covidien Lp Systems and methods for drive pressure spontaneous ventilation
US11931509B2 (en) 2017-11-14 2024-03-19 Covidien Lp Systems and methods for drive pressure spontaneous ventilation
US11517691B2 (en) 2018-09-07 2022-12-06 Covidien Lp Methods and systems for high pressure controlled ventilation
US11672934B2 (en) 2020-05-12 2023-06-13 Covidien Lp Remote ventilator adjustment

Also Published As

Publication number Publication date
US7246618B2 (en) 2007-07-24
US20180154096A1 (en) 2018-06-07
US20150359983A1 (en) 2015-12-17
US8573205B2 (en) 2013-11-05
US20030111078A1 (en) 2003-06-19
US20080072901A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
US20060174884A1 (en) Ventilation method and control of a ventilator based on same
US11534563B2 (en) Methods, systems and apparatus for paced breathing
US20190381264A1 (en) Ventilator Apparatus and System of Ventilation
US8684001B2 (en) Apparatus for providing positive airway pressure to a patient
US8794234B2 (en) Inversion-based feed-forward compensation of inspiratory trigger dynamics in medical ventilators
CA2726604C (en) Ventilator apparatus and system for ventilation
WO1998025664A1 (en) Method and apparatus for providing ventilatory support to a patient
Brown et al. Principles of artificial ventilation
Hess et al. Mechanical ventilation
CN112057714B (en) Breathing machine
Tan Airway Pressure Release Ventilation (APRV) in the Management of Respiratory Distress Syndrome (RDS): A Protocol and Call for Further Research.
Schneider et al. Mechanical Ventilation
Macnaughton et al. Modes of mechanical ventilation
Wong Mechanical ventilation
Leger et al. Choice of Devices, Ventilators, Interfaces, and Monitors

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTENSIVE CARE ON-LINE NETWORK, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HABASHI, NADER M.;REEL/FRAME:024651/0457

Effective date: 20100708

AS Assignment

Owner name: HABASHI, NADER M., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INTENSIVE CARE ON-LINE NETWORK, INC.;REEL/FRAME:033722/0395

Effective date: 20140911

AS Assignment

Owner name: HABASHI, NADER M., MARYLAND

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBER 11368807 PREVIOUSLY RECORDED AT REEL: 033722 FRAME: 0395. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:INTENSIVE CARE ON-LINE NETWORK, INC.;REEL/FRAME:034630/0705

Effective date: 20140911

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION